Related Experiment Videos
Abdominal candidiasis in surgical patients
S M Alden1, E Frank, L Flancbaum
1UMDNJ-Robert Wood Johnson Medical School, Department of Surgery, New Brunswick 08903.
The American Surgeon
|January 1, 1989
Summary
Abdominal candidiasis is a serious threat in critically ill surgical patients. Early treatment with Amphotericin B is safe and improves outcomes, even with concurrent antibiotics.
Area of Science:
- Critical Care Medicine
- Surgical Infections
- Mycology
Background:
- Abdominal candidiasis is an emerging complication in critically ill surgical patients.
- Optimal management strategies remain undefined, necessitating further research.
Purpose of the Study:
- To evaluate the management and outcomes of abdominal candidiasis in critically ill surgical patients.
- To assess the efficacy and safety of Amphotericin B treatment.
Main Methods:
- Retrospective analysis of 16 critically ill surgical patients with abdominal candidiasis over 36 months.
- Treatment involved Amphotericin B, with detailed recording of predisposing factors and outcomes.
Main Results:
- Gastrointestinal mucosal violation was the most common precipitating event.
- Amphotericin B was safely administered, eradicating infection in 10 patients.
- Early treatment (within 7 days) correlated with reduced Amphotericin B dosage and better outcomes.
Conclusions:
- Abdominal candidiasis is a potentially lethal infection requiring aggressive treatment.
- Amphotericin B is a safe and effective treatment option.
- Concurrent antibiotic therapy can be continued during Amphotericin B treatment.